Pictet Asset Management
NBIX icon

Pictet Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Pictet Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.9M Sell
602,643
-174,291
-22% -$23.1M 0.08% 243
2025
Q4 		$110M Buy
776,934
+83,488
+12% +$12.1M 0.11% 205
2025
Q3 		$97.3M Sell
693,446
-2,676
-0.4% -$363K 0.09% 222
2025
Q2 		$87.5M Buy
696,122
+308,548
+80% +$35.4M 0.09% 224
2025
Q1 		$43.1M Sell
387,574
-223,545
-37% -$28.3M 0.05% 336
2024
Q4 		$83.4M Sell
611,119
-231,078
-27% -$28.6M 0.09% 228
2024
Q3 		$97M Sell
842,197
-29,127
-3% -$3.99M 0.11% 201
2024
Q2 		$120M Sell
871,324
-210,125
-19% -$28.8M 0.14% 173
2024
Q1 		$149M Sell
1,081,449
-131,864
-11% -$18M 0.16% 164
2023
Q4 		$160M Buy
1,213,313
+169,863
+16% +$19.6M 0.18% 147
2023
Q3 		$117M Buy
+1,043,450
New +$110M 0.14% 176

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management's NBIX Position: Q1 2026 in Review

Pictet Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 22% in Q1 2026, selling an estimated $23.1M and leaving 602,643 shares worth $78.9M. The position accounts for 0.08% of the portfolio, ranked #243.

Pictet Asset Management first reported a position in NBIX in Q3 2023 and has held it in 11 quarters since. The position peaked at $160M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Pictet Asset Management held 602,643 shares of Neurocrine Biosciences worth $78.9M as of Q1 2026.
  • Pictet Asset Management sold 174,291 Neurocrine Biosciences shares in Q1 2026, an estimated $23.1M.
  • Neurocrine Biosciences made up 0.08% of Pictet Asset Management's portfolio in Q1 2026, its #243 holding.
  • Pictet Asset Management first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Neurocrine Biosciences position peaked at $160M in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.